Company Overview
Snapshot
Founded in May 2019 by Guy Yachin, Xerient operates with 1–10 employees. The company has raised $5.03M across three funding rounds from two investors.
Business overview
Xerient is a Health Tech & Life Sciences company focused on addressing unmet needs in cancer treatment, specifically within abdominal and gastrointestinal cancers. The company develops novel therapeutics and diagnostic technologies to improve survival rates for patients with hard-to-treat cancers, beginning with solutions for pancreatic cancer. Xerient operates in the Pharma & Medical Biotechnology sector, with a focus on Drugs Discovery & Development, targeting healthcare providers.
Log in to access full profile ›Company Intelligence Q&A
- When was Xerient founded?
- Xerient was founded in May 2019 by Guy Yachin.
- What is Xerient's primary focus in cancer treatment?
- Xerient is focused on developing novel therapeutics and diagnostic technologies for abdominal and gastrointestinal cancers, starting with pancreatic cancer, to improve patient survival.